C12N 2740/16222
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/16222 (New viral proteins or individual genes, new structural or functional aspects of) appears on 766 US grants and 669 published applications in this corpus.
Search patents in C12N- Granted patents
- 766
- Published applications
- 669
- Assignees
- 435
- Inventors
- 1,357
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 5 | 0 |
| 1990 | 0 | 0 |
| 1991 | 11 | 0 |
| 1992 | 16 | 0 |
| 1993 | 13 | 0 |
| 1994 | 13 | 0 |
| 1995 | 12 | 0 |
| 1996 | 26 | 0 |
| 1997 | 36 | 0 |
| 1998 | 74 | 0 |
| 1999 | 38 | 0 |
| 2000 | 41 | 0 |
| 2001 | 36 | 3 |
| 2002 | 35 | 36 |
| 2003 | 37 | 78 |
| 2004 | 18 | 53 |
| 2005 | 9 | 56 |
| 2006 | 23 | 41 |
| 2007 | 20 | 48 |
| 2008 | 23 | 36 |
| 2009 | 35 | 41 |
| 2010 | 30 | 42 |
| 2011 | 22 | 37 |
| 2012 | 23 | 31 |
| 2013 | 14 | 13 |
| 2014 | 22 | 16 |
| 2015 | 20 | 17 |
| 2016 | 19 | 18 |
| 2017 | 16 | 12 |
| 2018 | 12 | 14 |
| 2019 | 12 | 15 |
| 2020 | 11 | 9 |
| 2021 | 12 | 15 |
| 2022 | 8 | 14 |
| 2023 | 4 | 8 |
| 2024 | 8 | 3 |
| 2025 | 3 | 6 |
| 2026 | 5 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for inducing an immune response using conserved element constructs18 Aug 2026US 12,709,635 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Compositions and methods for targeted delivery of CRISPR-Cas effector polypeptides and transgenes3 Mar 2026US 12,565,647 B2The Regents of the University of California
- Highly networked immunogen composition17 Feb 2026US 12,551,547 B2Massachusetts Eye and Ear Infirmary
- Modulation of protein degradation10 Feb 2026US 12,546,776 B2Orionis Biosciences BV
- Compositions and methods for treating HIV infection and reversing HIV latency6 Jan 2026US 12,514,921 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Recombinant enzyme for the accurate insertion of dna sequences in eukaryotic cells1 Oct 2026US 2026/0297624 A1Rensselaer Polytechnic Institute
- Directed evolution of engineered virus-like particles (evlps)23 Jul 2026US 2026/0209747 A1President and Fellows of Harvard College
- Compositions and Methods for Targeted Delivery of CRISPR-CAS Effector Polypeptides and Transgenes28 May 2026US 2026/0146247 A1The Regents of the University of California
- Highly networked immunogen composition14 May 2026US 2026/0130984 A1Massachusetts Eye and Ear Infirmary
- Modulation of protein degradation14 May 2026US 2026/0133195 A1Orionis Biosciences BV
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies319US 5,558,864 AMerck Patent GmbH · 1996
- Expression using fused genes providing for protein product297US 4,751,180 AChiron Corporation · 1988
- Genetic immunization277US 5,593,972 AThe Trustees of the University of Pennsylvania · 1997
- Recombinant negative strand RNA virus expression-systems218US 5,166,057 AMount Sinai School of Medicine of the City University of New York · 1992